Cetera Investment Advisers Editas Medicine, Inc. Transaction History

Cetera Investment Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $190,761 - $291,495	-7,185 Closed	0 $0
Q3 2021 Nov 16, 2021	BUY	$39.27 - $72.94 $48,145 - $89,424	1,226 Added 20.57%	7,185 $295,000
Q2 2021 Aug 13, 2021	BUY	$31.29 - $56.64 $37,016 - $67,005	1,183 Added 24.77%	5,959 $338,000
Q1 2021 May 17, 2021	SELL	$39.71 - $90.58 $62,622 - $142,844	-1,577 Reduced 24.82%	4,776 $201,000
Q4 2020 Feb 17, 2021	BUY	$27.07 - $84.35 $171,975 - $535,875	6,353 New	6,353 $445,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $144M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

Stay updated on Cetera Investment Advisers with notifications on news.